{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:00:15Z","timestamp":1782122415706,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100567","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:28:13Z","timestamp":1660912093000},"page":"100567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)"],"prefix":"10.1016","volume":"7","author":[{"given":"D.","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chiarazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Famiglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gervaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Oneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rapisardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lavacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100567_bib1","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100567_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.annonc.2019.10.007","article-title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","volume":"31","author":"Martinelli","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100567_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100567_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100567_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100567_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities","volume":"37","author":"Porru","year":"2018","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100567_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100567_bib8","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2093","article-title":"LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"32","author":"Weiss","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100567_bib9","article-title":"Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100567_bib10","first-page":"219","article-title":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","volume":"19","author":"Schirripa","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100567_bib11","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/cancers12071919","article-title":"Study of Ras mutations\u2019 prognostic value in metastatic colorectal cancer: STORIA analysis","volume":"12","author":"Ottaiano","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100567_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","article-title":"Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer","volume":"27","author":"Fakih","year":"2022","journal-title":"The Oncologist"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100567_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/onco.13870","article-title":"The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study","volume":"26","author":"Chida","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100567_bib14","doi-asserted-by":"crossref","first-page":"736104","DOI":"10.3389\/fonc.2021.736104","article-title":"Retrospective comparative analysis of KRAS G12C vs. other KRAS mutations in mCRC patients treated with first-line chemotherapy doublet\u00a0+ bevacizumab","volume":"11","author":"Giampieri","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2022.100567_bib15","doi-asserted-by":"crossref","first-page":"826073","DOI":"10.3389\/fonc.2022.826073","article-title":"KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer","volume":"12","author":"Osterlund","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100567_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRASG12C somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100567_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","article-title":"Precision oncology in metastatic colorectal cancer - from biology to medicine","volume":"18","author":"Di Nicolantonio","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100567_bib18","doi-asserted-by":"crossref","first-page":"102023","DOI":"10.1016\/j.ctrv.2020.102023","article-title":"Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed?","volume":"86","author":"Martini","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100567_bib19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2022.100567_bib20","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100567_bib21","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100567_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100567_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100567_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.esmoop.2022.100567_bib25","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100567_bib26","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100567_bib27","first-page":"372","article-title":"Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"issue":"28","key":"10.1016\/j.esmoop.2022.100567_bib28","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100567_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2022.100567_bib30","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/cancers13153863","article-title":"Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience","volume":"13","author":"Lavacchi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9863","key":"10.1016\/j.esmoop.2022.100567_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.esmoop.2022.100567_bib32","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100567_bib33","doi-asserted-by":"crossref","first-page":"e000177","DOI":"10.1136\/esmoopen-2017-000177","article-title":"Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment","volume":"2","author":"Martinelli","year":"2017","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100567_bib34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100567_bib35","doi-asserted-by":"crossref","first-page":"100156","DOI":"10.1016\/j.esmoop.2021.100156","article-title":"Strategies to tackle RAS-mutated metastatic colorectal cancer","volume":"6","author":"Patelli","year":"2021","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100567_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100567_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.esmoop.2022.100567_bib38","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","volume":"38","author":"Cremolini","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:34Z","timestamp":1761856174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922001958"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100567","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100567"}}